Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib

Por Swords, Ronan, Mahalingam, Devalingam, Padmanabhan, Swaminathan, Carew, Jennifer, Giles, Francis
Publicado em 2009

Elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia

Por Giles, Francis, Rizzieri, David, Swords, Ronan, Jacobsen, Tove Flem, O'Brien, Susan
Publicado em 2012

A Case of AML Characterized by a Novel t(4;15)(q31;q22) Translocation That Confers a Growth-Stimulatory Response to Retinoid-Based Therapy

Por Watts, Justin M., Perez, Aymee, Pereira, Lutecia, Fan, Yao-Shan, Brown, Geoffrey, Vega, Francisco, Petrie, Kevin, Swords, Ronan T., Zelent, Arthur
Publicado no Int J Mol Sci (2017)

Powered bone marrow biopsy procedures produce larger core specimens, with less pain, in less time than with standard manual devices

Por Miller, Larry J., Philbeck, Thomas E., Montez, Diana F., Puga, Tatiana A., Brodie, Kim E., Cohen, Stephen C., Spadaccini, Cathy, Swords, Ronan, Brenner, Andrew J.
Publicado em 2011

Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation

Por Carew, Jennifer S, Medina, Ernest C, Esquivel II, Juan A, Mahalingam, Devalingam, Swords, Ronan, Kelly, Kevin, Zhang, Hui, Huang, Peng, Mita, Alain C, Mita, Monica M, Giles, Francis J, Nawrocki, Steffan T
Publicado em 2010

Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias

Por Bansal, Hima, Bansal, Sanjay, Rao, Manjeet, Foley, Kevin P., Sang, Jim, Proia, David A., Blackman, Ronald K., Ying, Weiwen, Barsoum, James, Baer, Maria R., Kelly, Kevin, Swords, Ronan, Tomlinson, Gail E., Battiwalla, Minoo, Giles, Francis J., Lee, Kelvin P., Padmanabhan, Swaminathan
Publicado em 2010

p53‐Based strategy to reduce hematological toxicity of chemotherapy: A proof of principle study

Por Ha, Chul S., Michalek, Joel E., Elledge, Richard, Kelly, Kevin R., Ganapathy, Suthakar, Su, Hang, Jenkins, Carol A., Argiris, Athanassios, Swords, Ronan, Eng, Tony Y., Karnad, Anand, Crownover, Richard L., Swanson, Gregory P., Goros, Martin, Pollock, Brad H., Yuan, Zhi-Min
Publicado no Mol Oncol (2015)

Ex-vivo Sensitivity Profiling to Guide Clinical Decision Making in Acute Myeloid Leukemia: A Pilot Study

Por Swords, Ronan T, Azzam, Diana, Al-Ali, Hassan, Lohse, Ines, Volmar, Claude-Henry, Watts, Justin M., Perez, Aymee, Rodriguez, Ana, Vargas, Fernando, Elias, Roy, Vega, Francisco, Zelent, Arthur, Brothers, Shaun P., Abbasi, Taher, Trent, Jonathan, Rangwala, Shaukat, Deutsch, Yehuda, Conneally, Eibhlin, Drusbosky, Leylah, Cogle, Christopher R., Wahlestedt, Claes
Publicado no Leuk Res (2017)

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies

Por Kurtz, Stephen E., Eide, Christopher A., Kaempf, Andy, Khanna, Vishesh, Savage, Samantha L., Rofelty, Angela, English, Isabel, Ho, Hibery, Pandya, Ravi, Bolosky, William J., Poon, Hoifung, Deininger, Michael W., Collins, Robert, Swords, Ronan T., Watts, Justin, Pollyea, Daniel A., Medeiros, Bruno C., Traer, Elie, Tognon, Cristina E., Mori, Motomi, Druker, Brian J., Tyner, Jeffrey W.
Publicado no Proc Natl Acad Sci U S A (2017)

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Por Stein, Eytan M., DiNardo, Courtney D., Pollyea, Daniel A., Fathi, Amir T., Roboz, Gail J., Altman, Jessica K., Stone, Richard M., DeAngelo, Daniel J., Levine, Ross L., Flinn, Ian W., Kantarjian, Hagop M., Collins, Robert, Patel, Manish R., Frankel, Arthur E., Stein, Anthony, Sekeres, Mikkael A., Swords, Ronan T., Medeiros, Bruno C., Willekens, Christophe, Vyas, Paresh, Tosolini, Alessandra, Xu, Qiang, Knight, Robert D., Yen, Katharine E., Agresta, Sam, de Botton, Stephane, Tallman, Martin S.
Publicado no Blood (2017)